Rifapentine access in Europe: growing concerns over key tuberculosis treatment component

Lack of access to rifapentine in Europe denies patients optimal care for active tuberculosis and latent tuberculosis infection, and deprives healthcare providers of adequate tools to pursue tuberculosis control and elimination https://bit.ly/3jz85eh

Detalles Bibliográficos
Autores principales: Guglielmetti, Lorenzo, Günther, Gunar, Leu, Claude, Cirillo, Daniela, Duarte, Raquel, Garcia-Basteiro, Alberto L., Goletti, Delia, Jankovic, Mateja, Kuksa, Liga, Maurer, Florian P., Méchaï, Frédéric, Tiberi, Simon, van Leth, Frank, Veziris, Nicolas, Lange, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Agora
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186306/
https://www.ncbi.nlm.nih.gov/pubmed/35589114
http://dx.doi.org/10.1183/13993003.00388-2022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186306/
https://www.ncbi.nlm.nih.gov/pubmed/35589114
http://dx.doi.org/10.1183/13993003.00388-2022

Ejemplares similares